Dyadic International Inc. and bYoRNA SAS partnered to advance innovative bioproduction technologies for scaling up the production of therapeutic mRNA from C1-Cells.

Global biotech Dyadic International Inc. and French bYoRNA SAS officially sealed a strategic partnership on the 26^th of September aimed at advancing disruptive bioproduction technologies. The collaboration is set to explore the production of high-quality messenger RNA (mRNA) using Dyadic’s C1 protein production platform, designed to cater to the demand for protein bioproduction while simultaneously addressing clinical requirements for biopharmaceutical products and alternative proteins. With bYoRNA’s focus and expertise on the scalable production of cost-effective therapeutic mRNA, mRNA will be made more accessible and cost-effective, particularly for patients in underserved regions, as the global mRNA market is projected to grow significantly.

“The COVID-19 pandemic brought mRNA technology to the forefront, showing its potential to prevent and treat diseases. Within this collaboration, we will combine our respective technologies to try to express “bio” RNA from Dyadic’s eukaryotic C1-cells, to design, develop and commercialise messenger RNA products,” said Pascal Viguié, bYoRNA’s Chief Executive Officer. If successful, Dyadic may receive milestone payments and a licensing option. The partnership seeks to provide lower-cost mRNA products for a broader global population, particularly for vaccines and therapies.